2014New England Journal of MedicineRequires access

Stool DNA and Colorectal-Cancer Screening

Douglas J. Robertson, Jason A. Dominitz

Open publisher page 18 citations

Abstract

Colorectal-cancer screening in the United States is a success story. The American Cancer Society recently reported that rates of death from colorectal cancer are down by 46% from their peak.1 There is good evidence that screening efforts have played an important role in the trend.2 However, work remains to be done, since approximately one third of Americans report not being current with screening.3 One approach to increase screening uptake is to broaden the available test options. On the basis of current U.S. Preventive Services Task Force guidelines, there are three recommended options: fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. . . .

About this research paper

What this paper is about

Colorectal-cancer screening in the United States is a success story. The American Cancer Society recently reported that rates of death from colorectal cancer are down by 46% from their peak.1 There is good evidence that screening efforts have played an important role in the trend.2 However, work remains to be done, since approximately one third of Americans report not being current with screening.3 One approach to increase screening uptake is to broaden the available test options. On the basis of current U.S. Preventive Services Task Force guidelines, there are three recommended options: fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. . . .

Why it matters

OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Colorectal-cancer screening in the United States is a success story. The American Cancer Society recently reported that rates of death from colorectal cancer are down by 46% from their peak.1 There is good evidence that screening efforts have played an important role in the trend.2 However, work remains to be done, since approximately one third of Americans report not being current with screening.3 One approach to increase screening uptake is to broaden the available test options. On the basis of current U.S. Preventive Services Task Force guidelines, there are three recommended options: fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. . . .

Key concepts: Sigmoidoscopy, Medicine, Fecal occult blood, Colorectal cancer, Colonoscopy, Colorectal cancer screening, Task force, Cancer screening

Related papers

Back to paper searchBrowse research topicsOriginal source
Stool DNA and Colorectal-Cancer Screening — Research Paper | ScholarLens